Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 20304499)

1.

Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.

Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, Chetrit N, Bakshi E, Zadok D, Tomkins O, Litvin G, Jacobson KA, Fishman S, Harpaz Z, Farbstein M, Yehuda SB, Silverman MH, Kerns WD, Bristol DR, Cohn I, Fishman P.

Ophthalmology. 2010 Jul;117(7):1287-93. doi: 10.1016/j.ophtha.2009.11.029. Epub 2010 Mar 20.

2.

Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.

Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N; Rebamipide Ophthalmic Suspension Phase II Study Group.

Ophthalmology. 2012 Dec;119(12):2471-8. doi: 10.1016/j.ophtha.2012.06.052. Epub 2012 Sep 23.

PMID:
23009892
4.

Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.

Liew SH, Nichols KK, Klamerus KJ, Li JZ, Zhang M, Foulks GN.

Ophthalmology. 2012 Jul;119(7):1328-35. doi: 10.1016/j.ophtha.2012.01.028. Epub 2012 Apr 22.

PMID:
22525048
5.

Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.

Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K; Diquafosol Ophthalmic Solution Phase 2 Study Group.

Ophthalmology. 2012 Oct;119(10):1954-60. doi: 10.1016/j.ophtha.2012.04.010. Epub 2012 Jun 26.

PMID:
22739038
6.

Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

Sall K, Stevenson OD, Mundorf TK, Reis BL.

Ophthalmology. 2000 Apr;107(4):631-9. Erratum in: Ophthalmology 2000 Jul;107(7):1220.

PMID:
10768324
7.

A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.

Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N; Rebamipide Ophthalmic Suspension Phase 3 Study Group.

Ophthalmology. 2013 Jun;120(6):1158-65. doi: 10.1016/j.ophtha.2012.12.022. Epub 2013 Mar 13.

PMID:
23490326
8.

Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ.

Cornea. 2004 Nov;23(8):784-92. Erratum in: Cornea. 2007 May;26(4):514.

PMID:
15502479
9.

CF101 for dry eye.

Ashar JN, Mathur A, Sangwan V.

Ophthalmology. 2011 May;118(5):1011-2; author reply 1012. doi: 10.1016/j.ophtha.2010.11.026. No abstract available.

PMID:
21539995
10.

Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.

Sheppard JD, Torkildsen GL, Lonsdale JD, D'Ambrosio FA Jr, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP; OPUS-1 Study Group.

Ophthalmology. 2014 Feb;121(2):475-83. doi: 10.1016/j.ophtha.2013.09.015. Epub 2013 Nov 26.

PMID:
24289915
11.

Targeting the A3 adenosine receptor for glaucoma treatment (review).

Fishman P, Cohen S, Bar-Yehuda S.

Mol Med Rep. 2013 Jun;7(6):1723-5. doi: 10.3892/mmr.2013.1413. Epub 2013 Apr 4. Review.

PMID:
23563604
12.

Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial.

David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P.

J Eur Acad Dermatol Venereol. 2012 Mar;26(3):361-7. doi: 10.1111/j.1468-3083.2011.04078.x. Epub 2011 Apr 20.

PMID:
21504485
13.

A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.

Semba CP, Torkildsen GL, Lonsdale JD, McLaurin EB, Geffin JA, Mundorf TK, Kennedy KS, Ousler GW.

Am J Ophthalmol. 2012 Jun;153(6):1050-60.e1. doi: 10.1016/j.ajo.2011.11.003. Epub 2012 Feb 11.

PMID:
22330307
14.

Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.

Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, Jurkunas U, Schaumberg DA, Dana R.

JAMA Ophthalmol. 2013 Jun;131(6):715-23. doi: 10.1001/jamaophthalmol.2013.195.

15.
16.

Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome.

Sullivan LJ, McCurrach F, Lee S, Taylor HR, Rolando M, Marechal-Courtois C, Creuzot-Garcher C, Easty DL, Karabatsas C, Bingh Hoh M, Faschinger C, Laroche L.

Ophthalmology. 1997 Sep;104(9):1402-8.

PMID:
9307633
17.

A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye.

Kinoshita S, Awamura S, Nakamichi N, Suzuki H, Oshiden K, Yokoi N; Rebamipide Ophthalmic Suspension Long-term Study Group.

Am J Ophthalmol. 2014 Mar;157(3):576-83.e1. doi: 10.1016/j.ajo.2013.11.010. Epub 2013 Nov 16.

PMID:
24246575
18.

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.

Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P.

J Rheumatol. 2008 Jan;35(1):41-8. Epub 2007 Nov 15.

PMID:
18050382
19.

Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.

Byun YJ, Kim TI, Kwon SM, Seo KY, Kim SW, Kim EK, Park WC.

Cornea. 2012 May;31(5):509-13. doi: 10.1097/ICO.0b013e31818c69ef.

PMID:
19730097
20.

The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.

Su MY, Perry HD, Barsam A, Perry AR, Donnenfeld ED, Wittpenn JR, D'Aversa G.

Cornea. 2011 Oct;30(10):1098-104. doi: 10.1097/ICO.0b013e318206caee.

PMID:
21407074
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk